首页> 美国卫生研究院文献>Clinical and Diagnostic Laboratory Immunology >Lack of Interference with Immunogenicity of a Chimeric Alphavirus Replicon Particle-Based Influenza Vaccine by Preexisting Antivector Immunity
【2h】

Lack of Interference with Immunogenicity of a Chimeric Alphavirus Replicon Particle-Based Influenza Vaccine by Preexisting Antivector Immunity

机译:通过预先存在的抗载体免疫力来干扰嵌合的基于甲型病毒复制子颗粒的流感疫苗的免疫原性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antivector immunity has been recognized as a potential caveat of using virus-based vaccines. In the present study, an alphavirus-based replicon particle vaccine platform, which has demonstrated robust immunogenicity in animal models, was tested for effects of antivector immunity on immunogenicity against hemagglutinin of influenza virus as a target antigen and efficacy for protection against lethal challenge with the virus. Chimeric alphavirus-based replicon particles, comprising Venezuelan equine encephalitis virus nonstructural and Sindbis virus structural components, induced efficient protective antibody responses, which were not adversely influenced after multiple immunizations with the same vector expressing various antigens.
机译:抗载体免疫被认为是使用基于病毒的疫苗的潜在警告。在本研究中,测试了一种基于甲病毒的复制子颗粒疫苗平台,该平台已在动物模型中证明了强大的免疫原性,并测试了抗载体免疫作用对作为靶抗原的流感病毒血凝素的免疫原性的影响以及对付致死性攻击的功效。病毒。包含委内瑞拉马脑炎病毒非结构和Sindbis病毒结构成分的基于嵌合体α病毒的复制子颗粒诱导了有效的保护性抗体反应,在用表达多种抗原的相同载体多次免疫后,该反应没有受到不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号